The dynamics of serum tumor markers in predicting metastatic uveal melanoma (Part 1)

Anticancer Research

Volumn 31, Issue 1, 2011, Pages 345-349

  Barak, Vivian ^a   Kaiserman, Igor ^b   Frenkel, Shahar ^a   Hendler, Keren ^a   Kalickman, Inna ^a   Pe'er, Jacob ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Barzilai Hospital   (Israel)

Author keywords

Metastasis; MIA; OPN; S 100 ; TPS; Tumor markers; Uveal melanoma

Indexed keywords

MELANOMA INHIBITORY ACTIVITY; OSTEOPONTIN; PROTEIN S100B; SECRETORY PROTEIN; TISSUE POLYPEPTIDE ANTIGEN; TISSUE POLYPEPTIDE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; KINETICS; LIVER BIOPSY; LIVER METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ULTRASOUND; UVEA MELANOMA;

ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX PROTEINS; HUMANS; LIVER NEOPLASMS; MELANOMA; NEOPLASM PROTEINS; NERVE GROWTH FACTORS; OSTEOPONTIN; PEPTIDES; PROGNOSIS; S100 PROTEINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS;

EID: 79851498472     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Damato B: Developments in the management of uveal melanoma. Clin Exp Ophthalmol 32: 639-647, 2004.
2. Mudhar HS, Parsons MA, Sisley K, Rundle P, Singh A and Rennie IG: A critical appraisal of the prognostic and predictive factors for uveal malignant melanoma. Histopathol 45: 1-12, 2004. (Pubitemid 38969556)
3. Kivela T, Eskelin S and Kujala E: Metastatic uveal melanoma. Int Ophthalmol Clin 46: 133-149, 2006. (Pubitemid 44124236)
4. Frenkel S, Nir I, Hendler K, Lotem M, Eid A, Jurim O and Pe'er J: Long-term survival of uveal melanoma patients after surgery for liver metastases. Br J Ophthalmol 93(8): 1042-1046, 2009.
5. Kaiserman I, Amer R and Pe'er J: Liver function tests in metastatic uveal melanoma. Am J Ophthalmol 137(2): 236-243, 2004. (Pubitemid 38220994)
6. Bedikian AY: Metastatic uveal melanoma therapy: current options. Int Ophthalmol Clin 46: 151-166, 2006
7. Hannsson L, Hauschild A, Bonfrer JMG, Duffy J and Einarsson R: Tumor markers in malignant melanoma - EGTM (European Group on Tumor Markers) Guidelines. Tumor Biol 27(Suppl 1): 35-36, 2006.
8. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E and Christofer E: S-100β protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 56: 338-344, 1999. (Pubitemid 29240361)
9. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zitngibl H, Hein R, Stolz W and Buettner R: Melanoma-inhibiting activity: MIA - a novel serum marker for progression of malignant melanoma. Cancer Res 57: 3149-3153, 1997. (Pubitemid 27351728)
10. Schaller UC, Bosserhoff AK, Neubauer AS, Buettner R, Kampik A and Mueller AJ: MIA- a novel serum marker for uveal melanoma. Melanoma Res 12: 593-599, 2002.
11. Missotten GS, Korse CM, van Dehn CM, Linders TC, Keunen JE, Jager MJ and Bonfrer JM: S-100-beta protein and MIA protein in uveal melanoma screening. Tumor Biology 28: 63-69, 2007.
12. Kadkol S, Lyn A, Barak V, Kalickman I, Leach L, Valyi-Nagy K, Majumdar D, Setty S, Maniotis A, Folberg R and Pe'er J: Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. IOVS 47(3): 802-806, 2006. (Pubitemid 46768309)
13. Barak V, Frenkel S, Kalickman I, Maniotis AJ, Folberg R and Pe'er J: Serum markers to detect metastatic uveal melanoma. Anticancer Res 27: 1897-1900, 2007.
14. Barak V, Frenkel, S, Valyi-Nagy K, Leach L, Apushkin MA, Lin, AY, Kalickman I, Baumann N, Pe'er J, Maniotis AJ and Folberg R: Using the direct-injection model of early uveal melanoma hepatic metastasis to identify TPS as a potentially useful serum biomarker. IOVS 48: 4399-4402, 2007.
15. Folberg R, Leach L, Valyi-Nagy K, Lin AY, Marsha A, Apushkin MA, Ai Z, Barak V, Majumdar D, Pe'er J and Maniotis AJ: Modeling the behavior of uveal melanoma in the liver. IOVS 48: 2967-2974, 2007.
16. Haritoglou I, Wolf A, Maier T, Haritoglou C, Hein R and Schaller UC: Osteopontin and melanoma inhibitory activity: comparison of 2 serological tumor markers in metastatic uveal melanoma patients. Ophthalmologica 223: 239-243, 2009.
17. Reininger IW, Wolf A, Welge-Lussen U, Mueller AJ, Kampik A, and Shaller UC: Osteopontin as a serologic marker for uveal melanoma: results of a pilot study. Am J Ophthalmol 143: 705-707, 2007.
18. Donoso LA, Shields JA, Augsburger JA, Orth DH and Johnson P: Metastatic uveal melanoma: diffuse hepatic metastasis in a patient with concurrent normal serum enzyme levels and liver scan. Arch Ophthalmol 103: 758-758, 1985.
19. Molina R, Barak V, van Dalen A et al: Tumor markers in breast cancer-European Group on Tumor Markers (EGTM) recommendations. Tumor Biol 26: 281-293, 2005. (Pubitemid 41619458)
20. Van Dalen A, Barak V, Cremaschi A, Gion M, Molina R, Namer M, Stieber P, Sturgeon C and Einarsson R: The prognostic significance of increasing marker levels in metastatic breast cancer patients with clinically complete remission, partial remission or stable disease. Int J Biol Markers 13(1): 10-15, 1998. (Pubitemid 28356504)
21. Barak V, Aronson AC, Novikov I, Peretz T and Einarsson R: Prognostic significance of cytokeratin markers in breast cancer: a meta analysis tumor biology 31(Suppl 1): S41, 2010.